{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:49:08Z","timestamp":1791571748637,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12CA167540"],"award-info":[{"award-number":["K12CA167540"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005227","name":"Centers for Medicare and Medicaid Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005227","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["R24 HS19455"],"award-info":[{"award-number":["R24 HS19455"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013347","name":"Institute of Translational Health Sciences, University of Washington","doi-asserted-by":"publisher","award":["UL1 TR002345"],"award-info":[{"award-number":["UL1 TR002345"]}],"id":[{"id":"10.13039\/100013347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.clml.2019.09.618","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T19:33:23Z","timestamp":1570649603000},"page":"98-104.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma"],"prefix":"10.1016","volume":"20","author":[{"given":"Hira","family":"Mian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Fiala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya M.","family":"Wildes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.09.618_bib1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2014-10-609461","article-title":"Future distribution of multiple myeloma in the United States by sex, age, and race\/ethnicity","volume":"125","author":"Rosenberg","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.618_bib2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2019.09.618_bib3","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/leu.2016.380","article-title":"Trends in overall survival and costs of multiple myeloma, 2000-2014","volume":"31","author":"Fonseca","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.09.618_bib4","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.09.618_bib5","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2017.72.2447","article-title":"Subsidies for oral chemotherapy and use of immunomodulatory drugs among Medicare beneficiaries with myeloma","volume":"35","author":"Olszewski","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.09.618_bib6","doi-asserted-by":"crossref","first-page":"e20031","DOI":"10.1200\/JCO.2018.36.15_suppl.e20031","article-title":"Factors associated with non-adherence to lenalidomide in patients with multiple myeloma","volume":"36","author":"Leng","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.09.618_bib7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ctrv.2017.05.002","article-title":"Adherence to oral cancer therapy in older adults: the International Society of Geriatric Oncology (SIOG) taskforce recommendations","volume":"57","author":"Mislang","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clml.2019.09.618_bib8","doi-asserted-by":"crossref","first-page":"IV-3","DOI":"10.1097\/00005650-200208001-00002","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care"},{"key":"10.1016\/j.clml.2019.09.618_bib9","first-page":"978391","article-title":"Impact on medical cost, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for follicular lymphoma in elderly patients: an observational cohort study based on SEER-Medicare","volume":"2012","author":"Griffiths","year":"2012","journal-title":"J\u00a0Cancer Epidemiol"},{"key":"10.1016\/j.clml.2019.09.618_bib10","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","article-title":"Development of a comorbidity index using physician claims data","volume":"53","author":"Klabunde","year":"2000","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.clml.2019.09.618_bib11","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.clml.2019.09.618_bib12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1586\/14737140.2016.1159515","article-title":"Medication adherence to oral anticancer drugs: systematic review","volume":"16","author":"Huang","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clml.2019.09.618_bib13","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/pds.1230","article-title":"Methods for evaluation of medication adherence and persistence using automated databases","volume":"15","author":"Andrade","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clml.2019.09.618_bib14","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.09.618_bib15","doi-asserted-by":"crossref","first-page":"e0214446","DOI":"10.1371\/journal.pone.0214446","article-title":"Adherence to immunomodulatory drugs in patients with multiple myeloma","volume":"14","author":"Cransac","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2019.09.618_bib16","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/phar.1174","article-title":"Preliminary validation of self-assessment tool to measure imatinib adherence in patients with chronic myeloid leukemia","volume":"33","author":"Daouphars","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clml.2019.09.618_bib17","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3324\/haematol.2017.178103","article-title":"Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry","volume":"103","author":"Blimark","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.09.618_bib18","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1634\/theoncologist.2015-0405","article-title":"A\u00a0systematic review of adherence to oral antineoplastic therapies","volume":"21","author":"Greer","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2019.09.618_bib19","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/annonc\/mdt433","article-title":"Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review","volume":"25","author":"Puts","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2019.09.618_bib20","first-page":"397","article-title":"A\u00a0retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myeloma","volume":"19","author":"Lee","year":"2016","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.clml.2019.09.618_bib21","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1200\/JCO.2016.67.4184","article-title":"Factors associated with tyrosine kinase inhibitor initiation and adherence among medicare beneficiaries with chronic myeloid leukemia","volume":"34","author":"Winn","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.09.618_bib22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1158\/1940-6207.CAPR-13-0165","article-title":"Cognitive factors associated with adherence to oral antiestrogen therapy: results from the cognition in the study of tamoxifen and raloxifene (Co-STAR) study","volume":"7","author":"Klepin","year":"2014","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.clml.2019.09.618_bib23","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.618_bib24","doi-asserted-by":"crossref","first-page":"e0212117","DOI":"10.1371\/journal.pone.0212117","article-title":"Racial and ethnic disparities in medication adherence among privately insured patients in the United States","volume":"14","author":"Xie","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2019.09.618_bib25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.amjopharm.2010.03.002","article-title":"Racial differences in medication adherence: a cross-sectional study of Medicare enrollees","volume":"8","author":"Gerber","year":"2010","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.clml.2019.09.618_bib26","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1002\/cam4.1246","article-title":"Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-Medicare analysis","volume":"6","author":"Ailawadhi","year":"2017","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2019.09.618_bib27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41408-018-0102-7","article-title":"Disease and outcome disparities in multiple myeloma: exploring the role of race\/ethnicity in the Cooperative Group clinical trials","volume":"8","author":"Ailawadhi","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2019.09.618_bib28","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.ijnurstu.2008.02.009","article-title":"Older people and adherence with medication: a review of the literature","volume":"45","author":"Banning","year":"2008","journal-title":"Int J Nurs Stud"},{"key":"10.1016\/j.clml.2019.09.618_bib29","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/fampra\/cmr124","article-title":"The impact of polypharmacy on the health of Canadian seniors","volume":"29","author":"Reason","year":"2012","journal-title":"Fam Pract"},{"key":"10.1016\/j.clml.2019.09.618_bib30","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jgo.2016.07.010","article-title":"Polypharmacy and potentially inappropriate medication use in geriatric oncology","volume":"7","author":"Sharma","year":"2016","journal-title":"J\u00a0Geriatr Oncol"},{"key":"10.1016\/j.clml.2019.09.618_bib31","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jgo.2015.07.003","article-title":"A\u00a0pharmacist-led medication assessment used to determine a more precise estimation of the prevalence of complementary and alternative medication (CAM) use among ambulatory senior adults with cancer","volume":"6","author":"Nightingale","year":"2015","journal-title":"J\u00a0Geriatr Oncol"},{"key":"10.1016\/j.clml.2019.09.618_bib32","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/1078155208090624","article-title":"Use of prescription and nonprescription medications and supplements by cancer patients during chemotherapy: questionnaire validation","volume":"14","author":"Hanigan","year":"2008","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.clml.2019.09.618_bib33","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1046\/j.1464-5491.2002.00689.x","article-title":"Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study","volume":"19","author":"Donnan","year":"2002","journal-title":"Diabet Med"},{"key":"10.1016\/j.clml.2019.09.618_bib34","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1111\/ggi.13115","article-title":"Poor adherence to chronic obstructive pulmonary disease medications in primary care: role of age, disease burden and polypharmacy","volume":"17","author":"Vetrano","year":"2017","journal-title":"Geriatr Gerontol Int"},{"key":"10.1016\/j.clml.2019.09.618_bib35","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2147\/PPA.S95634","article-title":"Adherence to alendronic or risedronic acid treatment, combined or not to calcium and vitamin D, and related determinants in Italian patients with osteoporosis","volume":"10","author":"Calabria","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.clml.2019.09.618_bib36","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ijcard.2016.01.069","article-title":"Non-adherence to antihypertensive medication: the role of mental and physical comorbidity","volume":"207","author":"Calderon-Larranaga","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.clml.2019.09.618_bib37","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000450750","article-title":"Frequency and determinants of adherence to oral anticoagulants in stroke patients with atrial fibrillation in clinical practice","volume":"76","author":"Polymeris","year":"2016","journal-title":"Eur Neurol"},{"key":"10.1016\/j.clml.2019.09.618_bib38","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s002280100347","article-title":"Is cognitive impairment a risk factor for poor compliance among Japanese elderly in the community?","volume":"57","author":"Okuno","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clml.2019.09.618_bib39","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1200\/JOP.2016.018317","article-title":"Polypharmacy and adherence to adjuvant endocrine therapy for breast cancer","volume":"13","author":"Calip","year":"2017","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.clml.2019.09.618_bib40","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10549-006-9193-0","article-title":"Adherence to tamoxifen over the five-year course","volume":"99","author":"Lash","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clml.2019.09.618_bib42","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1634\/theoncologist.2011-0316","article-title":"Anthracycline regimen adherence in older patients with early breast cancer","volume":"17","author":"Barcenas","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2019.09.618_bib43","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1188\/14.ONF.274-285","article-title":"Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer","volume":"41","author":"Bender","year":"2014","journal-title":"Oncol Nurs Forum"},{"key":"10.1016\/j.clml.2019.09.618_bib44","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.2147\/PPA.S91534","article-title":"Self-reported adherence to oral cancer therapy: relationships with symptom distress, depression, and personal characteristics","volume":"9","author":"Berry","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.clml.2019.09.618_bib45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/0284186X.2013.844353","article-title":"Adherence and patients\u2019 experiences with the use of oral anticancer agents","volume":"53","author":"Timmers","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clml.2019.09.618_bib46","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s10549-011-1668-y","article-title":"Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?","volume":"129","author":"Guth","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clml.2019.09.618_bib47","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000328317","article-title":"Self-reported compliance with capecitabine: findings from a prospective cohort analysis","volume":"80","author":"Winterhalder","year":"2011","journal-title":"Oncology"},{"key":"10.1016\/j.clml.2019.09.618_bib48","doi-asserted-by":"crossref","first-page":"221","DOI":"10.6004\/jnccn.2018.7098","article-title":"Patient experiences with oral chemotherapy: adherence, symptoms, and quality of life","volume":"17","author":"Jacobs","year":"2019","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2019.09.618_bib49","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0090-4295(93)90265-C","article-title":"Patient compliance in treatment of prostate cancer with luteinizing hormone-releasing hormone (LHRH) agonist","volume":"42","author":"Shaheen","year":"1993","journal-title":"Urology"},{"key":"10.1016\/j.clml.2019.09.618_bib50","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1182\/blood.V128.22.4504.4504","article-title":"Early discontinuation of lenalidomide in patients with relapsing or refractory multiple myeloma: predictive factors for stopping in the real life","volume":"128","author":"Pistone","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.618_bib51","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/MLR.0b013e3182984c1f","article-title":"Group-based trajectory models: a new approach to classifying and predicting long-term medication adherence","volume":"51","author":"Franklin","year":"2013","journal-title":"Med Care"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019320051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019320051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:34:26Z","timestamp":1761870866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019320051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S2152265019320051"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.09.618","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.09.618","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}